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Long Term Results of Right Ventricular Outflow Tract 
Reconstruction with Homografts
Hye-Won  Kim,  M.D.*,  Dong-Man  Seo,  M.D.*,  Hong  Ju  Shin,  M.D.*, 
Jeong-Jun  Park,  M.D.*,  Tae-Jin  Yoon,  M.D.*
Background:  Homograft cardiac valves and valved-conduits have been available in our institute since 1992. We 
sought to determine the long-term outcome after right ventricular outflow tract (RVOT) reconstruction using homo-
grafts, and risk factors for reoperation were analyzed. Materials and Methods: We retrospectively reviewed 112 
patients who had undergone repair using 116 homografts between 1992 and 2008. Median age and body weight 
at operation were 31.2 months and 12.2 kg, respectively. The diagnoses were pulmonary atresia or stenosis with 
ventricular septal defect (n=93), congenital aortic valve diseases (n=15), and truncus arteriosus (N=8). Mean fol-
low-up duration was 79.2±14.8 months. Results: There were 10 early and 4 late deaths. Overall survival rate was 
89.6%, 88.7%, 86.1% at postoperative 1 year, 5 years and 10 years, respectively. Body weight at operation, car-
diopulmonary bypass (CPB) time and aortic cross-clamping (ACC) time were identified as risk factors for death. 
Forty-three reoperations were performed in thirty-nine patients. Freedom from reoperation was 97.0%, 77.8%, 35.0% 
at postoperative 1 year, 5 years and 10 years respectively. Small-sized graft was identified as a risk factor for re-
operation.  Conclusion: Although long-term survival after RVOT reconstruction with homografts was excellent, free-
dom from reoperation was unsatisfactory, especially in patients who had small grafts upon initial repair. Thus, alter-
native surgical strategies not using small grafts may need to be considered in this subset.
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INTRODUCTION
A  number  of  prosthetic  conduits  have  been  used  for  the 
correction  of  congenital  heart  defects.  Homograft  cardiac 
valves  and  valved-conduits  are  deemed  standing  out  in  terms 
of  durability,  easy  handling  and  availability  of  various  sizes 
[1].  However,  somatic  outgrowth  over  small-sized  conduit, 
calcification  of  the  aortic  or  pulmonary  homograft  wall,  and 
degeneration  of  the  valve  leaflets  are  the  caveats  when  using 
homograft is contemplated. From the time when the first case 
of heart transplantation was successfully performed in our in-
stitute  in  1992  [2],  we  started  to  use  homograft  cardiac 
valves  for  right  ventricular  outflow  tract  (RVOT)  reconstruc-
tion. In this study, we sought to determine the long-term out-
come after the use of homograft cardiac valves for RVOT re-
construction,  and  risk  factor  analysis  for  adverse  outcomes 
was  conducted. Long Term Results of Right Ventricular Outflow Tract Reconstruction with Homografts
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Fig. 1. Distribution of the patients according to the diagnosis. 
TGA=Transposition of the great arteries; cc-TGA=Congenitally cor-
rected transposition of the great arteries; DORV=Double outlet 
right ventricle.
Fig. 2. Distribution of the patients according to the age at opera-
tion.
Table 1. Characteristics of the patients 
Sex Male N:  73  (62.9%)
Female N:  43  (37.1%)
Age  at  operation Median 31.2  months 
  (6  days  to  17  years)
＜1  year  old N:  23  (19.8%)
1∼10  years  old  N:  76  (65.5%)
≥10  years  old N:  17  (14.7%)
Body  weight Median 12.3  kg 
  (2.4  kg  to  67.5  kg)
Diagnosis PA  with  VSD  N:  93  (80.2%)
  (including  TGA, 
 c c - T G A ,  D O R V  
 w i t h  V S D ,  P S )
Truncus  arteriosus N:  8  (6.9%)
Congential  aortic N:  15  (12.9%)
 v a l v e  d i s e a s e
CPB  time Median 173  minutes 
  (48  to  858  minutes)
ACC  time Median 76  minutes 
 ( 0  t o  2 3 7  m i n u t e s )
Type  of  conduit Aortic  homograft N:  62  (53.4%)
Pulmonic  homograft N:  53  (45.7%)
Missing N:  1  (0.9%)
Homograft  size Median 19  mm 
 ( 8  t o  2 9  m m )
≤16  mm  N:  32  (27.6%)
＞16  mm N:  72  (62.1%)
Missing N:  12  (10.3%)
PA  with  VSD=Pulmonary  atresia  with  ventricular  septal  defect; 
TGA=Transposition  of  the  great  arteries  (TGA);  cc-TGA=Co-
ngenitally  corrected  transposition  of  the  great  arteries;  DORV= 
Double  outlet  right  ventricle  (DORV);  PS=Pulmonary  stenosis; 
CPB=Cardiopulmonary  bypass;  ACC=Aortic  cross  clamp.
MATERIALS AND METHODS
    Retrospective  review  of  the  112  children  (younger  than  18 
years) who had undergone 116 RVOT reconstruction between 
1992  and  2008  was  performed.  Preoperative  diagnoses  were 
pulmonary  atresia  (PA)  or  stenosis  (PS)  with  ventricular  sep-
tal  defect  (VSD)  (including  transposition  of  the  great  arteries 
with  VSD  and  PS,  double  outlet  right  ventricle  with  VSD 
and  PS,  and  congenitally  corrected  transposition  of  great  ar-
teries  with  VSD  and  PS)  in  93,  congenital  aortic  valve  dis-
e a s e s  i n  1 5  a n d  t r u n c u s  a r t e r i o s u s  i n  8  ( F i g .  1 ) .  M e d i a n  a g e  
at  operation  was  31.2  months  (6  days∼17  years),  and  me-
dian  body  weight  at  operation  was  12.2  kg  (2.4∼67.5  kg). 
Age  distribution  at  repair  is  illustrated  in  the  Fig.  2.  There 
were  69  males  (69/112,  62.9%)  and  43  females  (43/112, 
37.1%).  Follow-up  duration  was  79.2±14.8  months,  and  fol-
low-up  was  complete  in  98  patients  (98/112,  87.5%).  Sixty- 
two  aortic  homografts (62/116, 53.4%) and fifty-three pulmo-
nary  homografts  (53/116,  47.5%)  were  used,  and  homograft 
type  could  not  be  identified  in  one  (1/116,  0.8%).  Median 
size  of  homografts  was  19  mm  (8∼2 9  m m )  ( T a b l e  1 ) .Hye-Won Kim, et al
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Fig. 3. Overall survival after the use of right ventricular outflow 
tract reconstruction using homograft conduits.
    Data  are  presented  as  frequencies,  medians  with  rages  or 
means  with  standard  deviations.  Survival  analysis  was  per-
formed by the Kaplan-Meier method, and unadjusted compar-
ison of the survival data between the variables of interest was 
conducted  using  log-rank  test.  All  statistical  analyses  were 
performed  using  SPSS  11.0  (SPSS  Inc,  Chicago,  IL),  and  a 
p-value  of  0.05  was  defined  as  being  significant.  Early  mor-
tality  was  defined  as  a  death  within  30  days  after  the  oper-
ation,  regardless  of  hospitalization  or  discharge.
RESULTS
    There  were  10  early  deaths  (10/112,  8.9%)  and  4  late 
deaths (4/112, 3.6%). Causes of early mortality were low car-
diac output in 8, sepsis in 1 and brain death in 1, and causes 
of  late  deaths  were  pneumonia  in  2,  right  heart  failure  in  1, 
and sudden death at home in 1. Preoperative diagnoses of the 
patients  with  early  or  late  mortality  were  pulmonary  atresia 
w i t h  V S D  i n  7 ,  t r u n c u s  a r t e r i o sus  in  3,  transposition  of  the 
great  arteries  with  VSD  and  PS  in  1,  congenitally  corrected 
transposition with VSD and PS in 1, double outlet right ven-
tricle  with  VSD  and  PS  in  1,  and  arotic  valve  disease  in  1. 
Age  at  operation  was  younger  than  12  months  in  5  and  be-
tween  1  and  10  years  in  9.  Overall  postoperative  survival  at 
1 year, 5 years, and 10 years were 89.6%, 88.7%, 86.1%, re-
spectively  (Fig.  3)  Fig.  4  illustrates  age-stratified  survival, 
which  shows  better  survival  in  patients  with  older  age  at 
repair.
    Univariate  analysis  revealed  that  body  weight  and  age  at 
repair,  cardiopulmonary  bypass  time,  and  the  diagnosis  of 
truncus  arteriosus  were  associated  with  the  increased  risk  of 
death. There was  no  difference in  survival  between  Ross and 
non-Ross  operation  groups  (Table  2).  Thirty-nine  patients  un-
derwent 43 reoperations. Freedom from reoperation at 1 year, 
5  years  and  10  years  after  the  operation  was  97.0%,  77.8%, 
and  35.0%,  respectively  (Fig.  5).  Age-stratified  freedom  from 
reoperation  is  plotted  in  Fig.  6,  which  also  shows  better  out-
come in patients who were older at repair. The mean interval 
between  initial  repair  and  reoperation  was  5.6±2.8  years. 
Univariate  analysis  for  reoperation  revealed  that  aortic  homo-
graft  and  small-sized  conduit  were  associated  with  an  in-
creased risk of reoperation. By multivariate analysis, however, 
only the size of the homograft remained significant (Table 3). 
Freedom  from  reoperation  stratified  by  the  size  of  the  homo-
grafts is plotted in Fig. 7, which shows that small sized con-
duit is associated with a higher risk of reoperation (p=0.08 by 
log rank test, p=0.022 by multivariate analysis). There was no 
difference  in  the  risk  of  reoperation  between  Ross  and 
non-Ross  operation  groups. 
DISCUSSION
　In  the  current  practice  of  right  ventricular  outflow  tract 
(RVOT)  reconstruction  for  patients  with  various  congenital 
heart  diseases,  strenuous  efforts  have  been  made  to  minimize 
the risk of conduit stenosis, valve regurgitation and right ven-
tricular dysfunction, which may lead to improvements in free-
dom  from  reoperation  on  long-term  follow-up.  A  number  of 
biologic  and  prosthetic  conduits,  such  as  homografts,  hetero-
grafts  and  synthetic  conduits,  have  been  developed  to  this 
end.  Although  homograft  cardiac  valves  were  introduced  for 
clinical  application  in  early  1960s,  the  use  of  homograft  car-
diac valves became popular again in 1980s, thanks to the de-
velopment  of  crypreservation technique.  Dearani  et  al.  [3]  re-
ported that surgical mortality after RVOT reconstruction using 
homograft decreased from 23.5% to 3.7% after 1980s, which, 
he  claimed,  could  be  attributed  to  the  development  of  cry-
opreservation technique. Homograft cardiac valves are easy to 
handle and  hemostatic,  and various sizes are  available. Given Long Term Results of Right Ventricular Outflow Tract Reconstruction with Homografts
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Fig. 4. Age stratified survival after the use of right ventricular outflow 
tract reconstruction using homograft conduits.
Table 2. Risk factors for mortality
Variables
Univariate
p-value
Multivariate
p-value HR 95%  CI
Sex 0.271
Body  weight 0.004 0.0042 0.817 0.711,  0.938
OP  age 0.040
Truncus  arteriosus 0.018
Non-Ross  OP 0.547
CPB  time ＜0.001 ＜0.0001 1.009 1.005,  1.012
ACC  time 0.091 0.0397 0.988 0.977,  0.999
Type  of  conduit 0.199
Conduit  size 0.167
CPB=Cardiopulmonary  bypass;  ACC=Aortic  cross  clamp.
Fig. 5. Freedom from reoperation after the use of right ventricu-
lar outflow tract reconstruction using homograft conduits.Hye-Won Kim, et al
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Fig. 6. Age-stratified freedom from reoperation after the use of right 
ventricular outflow tract reconstruction using homograft conduits.
Table 3. Risk factors for reoperation
Variables
Univariate Multivariate
p-value p-value HR 95%  CI
Sex 0.785
Body  weight 0.393
OP  age 0.447
Truncus  arteriosus 0.457
Non-Ross  OP 0.455
CPB  time 0.820
ACC  time 0.216
Type  of  conduit 0.018
Conduit  size 0.022 0.022 0.913 0.845∼0.987
CPB=Cardiopulmonary  bypass;  ACC=Aortic  cross  clamp.
Fig. 7. Freedom from reoperation after the use of right ventricular 
outflow tract reconstruction using homograft conduits stratified by 
conduit size.Long Term Results of Right Ventricular Outflow Tract Reconstruction with Homografts
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the fact that homografts lack growth potential, small-sized ho-
mograft  conduits  used  for  young  patients  may  well  fail  very 
soon.  Forbess  et  al.  [1]  stratified  patients  with  RVOT  re-
construction  using  homografts  according  to  their  age  at  oper-
ation  (infants,  1∼10  years,  and  older  than  10  years),  and 
freedom  from  conduit  failure  at  postoperative  5  years  was 
25%, 61% and 81%, respectively. In his study, risk factors for 
homograft  failure  were  identified  as  small  homograft  size, 
young  age  and  the  diagnosis  of  Truncus  arteriosus.  Brown  et 
al. [4] also reported that freedom from reoperation after RVOT 
reconstruction  using  homografts  at  postoperative  5  and  15 
years was 60% and 43%, respectively, even though survival at 
postoperative  15  years  was  up  to  80%.  Risk  factors  for  graft 
failure  in  our  study  were  identified  as  small  body  weight,  the 
diagnosis  of  truncus  arteriosus  (which  necessitate  early 
Rastelli-type  operation),  small-sized  graft  and  longer  aortic 
cross-clamping  time,  which  is  comparable  to  previous  reports. 
Even  though  small  sized  conduit  tends  to  fail  early,  the  avail-
a b i l i t y  o f  s m a l l  s i z e d  c o n d u i t  i s  o n e  o f  t h e  a d v a n t a g e s  o f  t h e  
use  of  homograft  conduits.  Lange  et  al.  [5]  claimed  that  there 
was  no  difference  in  conduit  failure  between  homografts  and 
bioprosthetic  valved  conduit  when  the  size  of  the  conduit  was 
smaller  than  15  mm,  while  the  outcome  of  the  latter  was  bet-
ter  than  that  of  the  former  when  the  size  of  the  conduit  was 
larger than 15 mm. Our study also revealed that freedom from 
reoperation after RVOT reconstruction using homografts small-
er than 17 mm at postoperative 5 and 10 years was 67.7% and 
21.4%, respectively, while freedom from reoperation of the pa-
tients who had homografts larger than 17 mm at postoperative 
5 and 10 years was 85.5% and 54.8%, respectively, which sig-
nifies  that  smaller  size  of  the  grafts  was  a  risk  factor  for 
reoperation.  Boething  et  al.  [6]  reported  almost  the  same  re-
sults  when  the  patients  were  stratified  according  to  the  size 
(19 mm) and age (10 years), speculating that homograft failure 
may be related to graft degeneration. In this regard, alternative 
conduits,  such  as  bovine  jugular  vein  graft  (Contegra
Ⓡ,  12∼
22  mm)  [7-9],  No-  React  treated  porcine  pulmonary  valved 
conduit  (Shelhigh
Ⓡ,  10∼24  mm)  [10],  freestyle  porcine  aortic 
root  (Medtronic
Ⓡ,  19∼29  mm)  [11],  have  been  developed  to 
overcome  the  shortcomings  of  homograft  conduits.  These  rela-
tively  new  conduits  are  thought  to  be  superior  to  homografts 
in  terms  of  the  superb  availability  of  various  sized  conduits, 
especially  very  small  sized  conduits  for  neonates  and  young 
infants. With respect to the intermediate-term outcome of these 
alternative  bio-prosthetic  materials,  Shelhigh
Ⓡ h a s  b e e n  r e -
ported to have a higher risk of graft stenosis by peel formation 
[12].  To  the  contrary,  Brown  et  al.  [7]  asserted  that  freedom 
from reoperation after the use of Contegra
Ⓡ at postoperative 2, 
5  and  7  years  are  88.9%,  87.6%  and  81.3%,  respectively, 
which  is  comparable  to  the  outcome  of  homograft  conduits, 
and Fiore  et  al.  [13]  showed  better  outcome  after  the  use 
of  Contergra
Ⓡ  compared  to  that  of  pulmonary  homografts. 
Rastan et al. [14], however, pointed out that the risk of reoper-
ation  after  this  new  conduit  is  as  high  as  homografts  in  pa-
tients  with  risk  factors,  such  as  young  age  at  operation,  diag-
nosis  of  truncus  arteriosus,  small  sized  conduit  (12  mm),  high 
postoperative  right  ventricular  pressure,  which  could  be  re-
g a r d e d  a s  c a v e a t s  f o r  t h e  u s e  o f  C o n t e g r a
Ⓡ.
　Synthetic  prosthetic  conduits  comprises  valveless  grafts  for 
temporary use to facilitate the growth of the peripheral pulmo-
nary  artery,  and  valved  conduits  composed  of  Dacron  or 
Polytetrafluoroethylene  (PTFE)  conduit  and  bioprosthetic  or 
mechanical valves. Belli et al. [15] reported long term outcome 
of  porcine-valve  seated  Dacron  conduit  (Hancock  conduit), 
which  showed  freedom  from  reoperation  at  postoperative  1,  5 
and  10  years  was  98%,  81%  and  32%,  respectively.  He  in-
sisted  that  this  valved  conduit  is  the  most  appropriate  material 
for patients with pulmonary hypertension, but it seems hard to 
say that this material is superior to other valved conduits, giv-
en  relatively  low  10-year  freedom  from  reoperation.
　With  respect  to  the  materials  to  substitute  for  the  function 
of  the  pulmonary  valve,  Brown  et  al.  [16]  supported  the  use 
of PTFE membrane due to its chemical inertness, which leads 
to  lower  risk  of  degeneration  or  calcification.  Ando  and 
Takahashi  [17]  reported  that  freedom  from  reoperation  and 
freedom  from  significant  pulmonary  regurgitation  at  10  years 
after  three-leaflet  formation  using  PTFE  membrane  were 
88.0±6.8%  and  75.0%,  respectively.  Despite  this  promising 
outcome in adults, Koh et al. [18] delineated that three-leaflet 
formation  using  PTFE  membrane  for  children  is  associated 
with  high  prevalence  of  reoperation.
　Durability  is  the  most  important  aspect  in  selecting  the 
types  of  conduits  in  the  pulmonary  position.  In  this  regard, 
mechanical  valve  seated  conduits  are  also  a  potential  alter-Hye-Won Kim, et al
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natives for selected subset. Haas et al reported excellent mid-
term results in 14 patents with multiple RVOT reconstruction 
procedures,  showing  that  mechanical  valve  function  was  nor-
mal  in  all  patients  while  trans-valvar  gradient  was  minimal 
[19].  He  asserted  that  in  a  subset  of  patients,  such  as  older 
patients  with  a  history  of  multiple  operations  without  contra-
indications  for  coumadization,  could  be  good  candidates  for 
receiving  mechanical  valve-seated  conduits.  Hörer  et  al.  [20] 
also  pointed  out  that  this  type  of  valved  conduits  have  bene-
fits of excellent hemodynamic profiles with slow development 
of  valve  regurgitation,  and,  thus,  could  be  indicated  for  pa-
tients  with  multiple  operations  and  arrhythmias.
CONCLUSION
    The  long-term  outcome  after  the  use  of  homograft  in  the 
pulmonary  position  was  excellent,  although  freedom  from  re-
operation  sharply  deteriorates  as  time  passes.  The  high  in-
cidence  of  reoperation  at  10  years  may  be  attributed  to  the 
use of small-sized conduits. Therefore, efforts should be made 
to  seek  alternative  small-sized  conduit  materials  for  young 
children, which could complement a number of benefits from 
medium  or  large-sized  homograft  conduits. 
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